BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Teva
Fish and Richardson
Johnson and Johnson
McKesson
McKinsey
Deloitte
Boehringer Ingelheim
Cerilliant
US Army

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021958

« Back to Dashboard

NDA 021958 describes LAMISIL AT, which is a drug marketed by Novartis and is included in two NDAs. It is available from two suppliers. Additional details are available on the LAMISIL AT profile page.

The generic ingredient in LAMISIL AT is terbinafine hydrochloride. There are twenty-six drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the terbinafine hydrochloride profile page.
Summary for 021958
Tradename:LAMISIL AT
Applicant:Novartis
Ingredient:terbinafine
Patents:0
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021958
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LAMISIL AT terbinafine GEL;TOPICAL 021958 NDA Novartis Consumer Health, Inc. 0067-6239 0067-6239-21 1 TUBE in 1 CONTAINER (0067-6239-21) > 6 g in 1 TUBE
LAMISIL AT terbinafine GEL;TOPICAL 021958 NDA Novartis Consumer Health, Inc. 0067-6239 0067-6239-42 1 TUBE in 1 CONTAINER (0067-6239-42) > 12 g in 1 TUBE

Profile for product number 001

Active Rx/OTC/Discontinued:OTCDosage:GEL;TOPICALStrength1%
Approval Date:Jul 24, 2006TE:RLD:Yes

Expired US Patents for NDA 021958

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 ➤ Subscribe ➤ Subscribe
Novartis LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 ➤ Subscribe ➤ Subscribe
Novartis LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Daiichi Sankyo
Cerilliant
Accenture
Farmers Insurance
Healthtrust
Covington
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot